title: Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.
abstract: OBJECTIVE
  Vascular endothelial growth factor (VEGF) has been reported to enhance vascular permeability and angiogenesis in the abdominal wall, thereby contributing to peritoneal dissemination with malignant ascites. We conducted this experimental study to find out if bevacizumab, a humanized monoclonal antibody against VEGF, had a suppressive effect on peritoneal dissemination from gastric cancer, in an experimental nude mouse model of peritoneal metastasis.
  
  
  METHODS
  Each mouse was treated with a single intraperitoneal (i.p.) injection of bevacizumab. Five mice were killed, and we measured their body weight, the mean number of tumor nodules, and the volume of ascites. We also extracted retroperitoneal tissues for histological examination, to count the frequency of mitosis, and to calculate the mitotic index. Another five mice were monitored until death, and their mean survival duration was calculated.
  
  
  RESULTS
  The volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group (P = 0.042 and P < 0.01, respectively). The survival curve of the therapy group was significantly higher than that of the nontherapy group (P = 0.005).
  
  
  CONCLUSIONS
  Bevacizumab may suppress peritoneal dissemination from gastric cancer.
authors.affiliation: Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.
authors.forename: Takuya
authors.initials: T
authors.lastname: Imaizumi
authors.forename: Keishiro
authors.initials: K
authors.lastname: Aoyagi
authors.forename: Motoshi
authors.initials: M
authors.lastname: Miyagi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001201:Ascites / Q000473:pathology; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008940:Mitotic Index; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000556:secondary*; D013274:Stomach Neoplasms / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab